KN-002 is under clinical development by Kinaset Therapeutics and currently in Phase I for Asthma. According to GlobalData, Phase I drugs for Asthma have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KN-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KN-002 overview

KN-002(formerly known as VR-588) is under development for the treatment of severe inflammatory airway diseases including asthma, chronic obstructive pulmonary disease (COPD) and other unspecified disease. It is a small molecule administered by inhalation. The drug candidate is a selective pan-JAK inhibitor. It act by targeting JAK1, JAK2, JAK3 and tyrosine kinase 2

Kinaset Therapeutics overview

Kinaset Therapeutics is a biopharma company. It is a developer of respiratory drugs intended to develop novel therapeutics for patients affected by intractable diseases, including severe asthma. The company’s novel respiratory therapeutics that can positively impact people affected by intractable diseases. Kinaset Therapeutics is focused on developing inhaled therapeutics. The company’s clinical candidate, KN-002, is a novel and non-invasive anti-inflammatory to treat all patients with severe asthma. Kinaset Therapeutics is headquartered in Medfield, Massachusetts, the US.

For a complete picture of KN-002’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.